TWI657086B - 做為人類免疫缺陷病毒複製抑制劑之5-(n-苯甲基四氫異喹啉-6-基)吡啶-3-基乙酸衍生物 - Google Patents

做為人類免疫缺陷病毒複製抑制劑之5-(n-苯甲基四氫異喹啉-6-基)吡啶-3-基乙酸衍生物 Download PDF

Info

Publication number
TWI657086B
TWI657086B TW105125345A TW105125345A TWI657086B TW I657086 B TWI657086 B TW I657086B TW 105125345 A TW105125345 A TW 105125345A TW 105125345 A TW105125345 A TW 105125345A TW I657086 B TWI657086 B TW I657086B
Authority
TW
Taiwan
Prior art keywords
butoxy
dimethylhexahydropyridin
acetic acid
dimethylpyridin
tetrahydroisoquinolin
Prior art date
Application number
TW105125345A
Other languages
English (en)
Chinese (zh)
Other versions
TW201718549A (zh
Inventor
凱爾J 伊斯曼
約翰F 凱多
B 那拉辛胡路 奈度
凱爾E 帕賽拉
王濤
尹志偉
張中興
Original Assignee
英商Viiv醫療保健英國(No.5)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56851651&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI657086(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 英商Viiv醫療保健英國(No.5)有限公司 filed Critical 英商Viiv醫療保健英國(No.5)有限公司
Publication of TW201718549A publication Critical patent/TW201718549A/zh
Application granted granted Critical
Publication of TWI657086B publication Critical patent/TWI657086B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW105125345A 2015-08-11 2016-08-09 做為人類免疫缺陷病毒複製抑制劑之5-(n-苯甲基四氫異喹啉-6-基)吡啶-3-基乙酸衍生物 TWI657086B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562203791P 2015-08-11 2015-08-11
US62/203,791 2015-08-11

Publications (2)

Publication Number Publication Date
TW201718549A TW201718549A (zh) 2017-06-01
TWI657086B true TWI657086B (zh) 2019-04-21

Family

ID=56851651

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105125345A TWI657086B (zh) 2015-08-11 2016-08-09 做為人類免疫缺陷病毒複製抑制劑之5-(n-苯甲基四氫異喹啉-6-基)吡啶-3-基乙酸衍生物

Country Status (23)

Country Link
US (2) US10189816B2 (cg-RX-API-DMAC7.html)
EP (1) EP3334716A1 (cg-RX-API-DMAC7.html)
JP (1) JP6782766B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180032649A (cg-RX-API-DMAC7.html)
CN (1) CN108137534A (cg-RX-API-DMAC7.html)
AR (1) AR105653A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016306089B2 (cg-RX-API-DMAC7.html)
CA (1) CA2994791A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018000363A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018001359A2 (cg-RX-API-DMAC7.html)
CR (1) CR20180091A (cg-RX-API-DMAC7.html)
DO (1) DOP2018000035A (cg-RX-API-DMAC7.html)
EA (1) EA033057B1 (cg-RX-API-DMAC7.html)
HK (1) HK1249503A1 (cg-RX-API-DMAC7.html)
IL (1) IL257240B (cg-RX-API-DMAC7.html)
MA (1) MA42614A (cg-RX-API-DMAC7.html)
MX (1) MX2018001722A (cg-RX-API-DMAC7.html)
PE (1) PE20181002A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018500294A1 (cg-RX-API-DMAC7.html)
TW (1) TWI657086B (cg-RX-API-DMAC7.html)
UA (1) UA120464C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017025917A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201800689B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718537A (zh) * 2015-08-12 2017-06-01 Viiv醫療保健英國(No.5)有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶-3-基乙酸衍生物
US10577353B2 (en) * 2015-08-12 2020-03-03 VIIV Healthcare UK (No.5) Limited 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3455217A1 (en) * 2016-05-11 2019-03-20 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3455214A1 (en) * 2016-05-11 2019-03-20 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2017195113A1 (en) * 2016-05-11 2017-11-16 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US20200016136A1 (en) * 2017-01-03 2020-01-16 Viiv Healthcare Uk (No. 5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
TW201835068A (zh) * 2017-01-03 2018-10-01 英商Viiv醫療保健英國(No.5)有限公司 作為人類免疫缺乏病毒複製之抑制劑之吡啶-3-基乙酸衍生物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010130034A1 (en) * 2009-05-15 2010-11-18 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
HRP20120328T2 (hr) 2007-11-15 2012-09-30 Gilead Sciences Inhibitori replikacije virusa humane imunodeficijencije
EP2574610A1 (en) 2007-11-15 2013-04-03 Gilead Sciences, Inc. Inhibitors of human immonodeficiency virus replication
KR20100097156A (ko) 2007-11-16 2010-09-02 베링거 인겔하임 인터내셔날 게엠베하 사람 면역결핍 바이러스 복제의 억제제
CA2705338A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
CA2781780C (en) 2009-12-23 2015-02-17 Katholieke Universiteit Leuven Novel antiviral compounds
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9580431B2 (en) 2013-03-13 2017-02-28 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP2970274B1 (en) 2013-03-14 2017-03-01 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US9637501B2 (en) 2014-02-20 2017-05-02 Viiv Healthcare Uk (No. 5) Limited Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication
US9193720B2 (en) 2014-02-20 2015-11-24 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US10577353B2 (en) * 2015-08-12 2020-03-03 VIIV Healthcare UK (No.5) Limited 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
AU2016305339A1 (en) * 2015-08-12 2018-03-01 VIIV Healthcare UK (No.5) Limited 5-(n-fused tricyclic Aryl tetrahydroisoquinolin-6-yl) pyridin-3- yl acetic acid derivatives as inhibitors of Human Immunodeficiency Virus replication
TW201718537A (zh) * 2015-08-12 2017-06-01 Viiv醫療保健英國(No.5)有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶-3-基乙酸衍生物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010130034A1 (en) * 2009-05-15 2010-11-18 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Di Santo R, et al."Inhibiting the HIV integration process: past, present, and the future.", J Med Chem. 2014 Feb 13;57(3):539-566.
DI SANTO R, ET AL: "Inhibiting the HIV integration process: past, present, and the future", J MED CHEM, vol. 57, no. 3, 13 February 2014 (2014-02-13), pages 539 - 566, XP055207945, doi:10.1021/jm400674a *

Also Published As

Publication number Publication date
DOP2018000035A (es) 2018-03-30
WO2017025917A1 (en) 2017-02-16
PE20181002A1 (es) 2018-06-26
MA42614A (fr) 2021-05-26
EA201890361A1 (ru) 2018-11-30
CR20180091A (es) 2018-06-13
IL257240B (en) 2020-02-27
PH12018500294A1 (en) 2018-08-13
JP2018522927A (ja) 2018-08-16
ZA201800689B (en) 2021-08-25
MX2018001722A (es) 2018-05-16
AU2016306089B2 (en) 2018-08-09
AR105653A1 (es) 2017-10-25
US10189816B2 (en) 2019-01-29
CA2994791A1 (en) 2017-02-16
HK1249503A1 (zh) 2018-11-02
JP6782766B2 (ja) 2020-11-11
CN108137534A (zh) 2018-06-08
TW201718549A (zh) 2017-06-01
EP3334716A1 (en) 2018-06-20
UA120464C2 (uk) 2019-12-10
IL257240A (en) 2018-03-29
US20190092754A1 (en) 2019-03-28
AU2016306089A1 (en) 2018-03-01
CO2018001359A2 (es) 2018-05-10
KR20180032649A (ko) 2018-03-30
US20180230129A1 (en) 2018-08-16
EA033057B1 (ru) 2019-08-30
CL2018000363A1 (es) 2018-07-06

Similar Documents

Publication Publication Date Title
TWI657086B (zh) 做為人類免疫缺陷病毒複製抑制劑之5-(n-苯甲基四氫異喹啉-6-基)吡啶-3-基乙酸衍生物
RU2720237C2 (ru) Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
TWI540134B (zh) 醫療性化合物
CN110713489B (zh) 杂芳基syk抑制剂
TWI714590B (zh) 吡啶並[3,4-d]嘧啶衍生物及其藥學上可被許可的鹽
CN106715430B (zh) 抑制瞬时型感受器电位a1离子通道
TW201738235A (zh) 可作為蛋白質調節劑之雜環醯胺
CN115028617A (zh) Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
US10065953B2 (en) Imidazo[1,2-A]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication
JP2018522909A (ja) ヒト免疫不全ウイルス複製の阻害剤としての5−(n−縮合三環式アリールテトラヒドロイソキノリン−6−イル)ピリジン−3−イル酢酸誘導体
JP2018522913A (ja) ヒト免疫不全ウイルス複製の阻害剤としての5−(n−[6,5]−縮合二環式アリールテトラヒドロイソキノリン−6−イル)ピリジン−3−イル酢酸誘導体
JP2019515003A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−3−イル酢酸誘導体
JP2018520162A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−3−イル酢酸誘導体
JP2019515939A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−3−イル酢酸誘導体
JP2019515000A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−3−イル酢酸誘導体
JP2018519349A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−3−イル酢酸誘導体
JP2018522924A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのイミダゾピリジン大環状化合物
HK40005958B (zh) 用於治疗癌症的吡唑并吡啶衍生物
HK1231868A1 (en) Heteroaryl syk inhibitors

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees